BioSpace News Archive

Zevra Therapeutics, Inc. today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at upcoming investor conferences in March 2024.

Cytokinetics, Incorporated, together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials.

Elevation Oncology, Inc. today announced that members of management will participate in upcoming investor conferences in March.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

PharmAust Limited is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy. Rates of disease progression in patients with Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58% for Cohort 2, when compared to an external control cohort (PRO-ACT database).

Smith+Nephew, the global medical technology company, announced they have entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research.

Volta Medical today announced CE (Conformité Européenne) Mark according to the new European Medical Device Regulation MDR 2017/745 for its Volta AF-Xplorer™, an AI companion that is cleared in the United States for the real-time manual or automatic annotation of spatiotemporal dispersions during AF and atrial tachycardia (AT) procedures.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA.

Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the publication of a peer-reviewed article titled, “A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity” in the journal OncoImmunology.